TY - JOUR
T1 - Effect of theophylline on substrate metabolism during exercise
AU - Raguso, Comasia A.
AU - Coggan, Andrew R.
AU - Sidossis, Labros S.
AU - Gastaldelli, Amalia
AU - Wolfe, Robert R.
N1 - Funding Information:
From the Metabolism Unit, Shriners Burns Institute, Galveston; and the Departments of Anesthesiology and Surgery, The University of Texas Medical Branch, Galveston, T~. Submitted December 31, 1995; accepted March 22, 1996. Supported by National Institutes of Health Grants No. DK 34817, DK46017, and GCRC 00073, and Grant No. 15849from the Shriners Hospital. Address reprint requests to Andrew R. Coggan, PhD, Shriners Burns Institute, 815 Market St, Galveston, TX 77550. Copyright © 1996 by W.B. Saunders Company 0026-0495/96/4509-0017503. 00/0
PY - 1996
Y1 - 1996
N2 - We tested the hypothesis that adenosine is involved in regulating substrate metabolism during exercise. Seven trained cyclists were studied during 30 minutes of exercise at approximately 75% maximal oxygen uptake (V̇O2max). Lipid metabolism was evaluated by infusing [2H5]glycerol and [1-13C]palmitate, and glucose kinetics were evaluated by infusing [6,6- 2H]glucose. Fat and carbohydrate oxidation were also measured by indirect calorimetry. The same subjects performed two identical exercise tests, but in one trial theophylline, a potent adenosine receptor antagonist, was infused for 1 hour before and throughout exercise. Theophylline did not increase whole-body lipolysis (glycerol rate of appearance [R(a)]) or free fatty acid (FFA) release during exercise, but fat oxidation was lower than control values (9.5 ± 3.0 v 18.0 ± 4.2 μol · min-1 · kg-1, P < .01). Glucose R(a) was not affected by theophylline infusion, but glucose uptake was lower (31.6 ± 4.1 v 40.4 ± 5.0 μmol · min-1 · kg-1, P < .05) and glucose concentration was higher (6.4 ± 0.6 v 5.8 ± 0.4 mmol/L, P < .05) than in the control trial. Total carbohydrate oxidation (302.3 ± 26.2 v 265.5 ± 11.7 μmol · min-1 · kg-1, P < .06), estimated muscle glycogenolysis (270.7 ± 23.1 v 225.1 ± 9.7 μmol · min-1 · kg-1, p < .05), and plasma lactate concentration (7.9 ± 1.6 v 5.9 ± 1.1 mmol/L, P < .001) were also higher during the theophylline trial. These data suggest that adenosine may play a role in stimulating glucose uptake and restraining glycogenolysis but not in limiting lipolysis during exercise.
AB - We tested the hypothesis that adenosine is involved in regulating substrate metabolism during exercise. Seven trained cyclists were studied during 30 minutes of exercise at approximately 75% maximal oxygen uptake (V̇O2max). Lipid metabolism was evaluated by infusing [2H5]glycerol and [1-13C]palmitate, and glucose kinetics were evaluated by infusing [6,6- 2H]glucose. Fat and carbohydrate oxidation were also measured by indirect calorimetry. The same subjects performed two identical exercise tests, but in one trial theophylline, a potent adenosine receptor antagonist, was infused for 1 hour before and throughout exercise. Theophylline did not increase whole-body lipolysis (glycerol rate of appearance [R(a)]) or free fatty acid (FFA) release during exercise, but fat oxidation was lower than control values (9.5 ± 3.0 v 18.0 ± 4.2 μol · min-1 · kg-1, P < .01). Glucose R(a) was not affected by theophylline infusion, but glucose uptake was lower (31.6 ± 4.1 v 40.4 ± 5.0 μmol · min-1 · kg-1, P < .05) and glucose concentration was higher (6.4 ± 0.6 v 5.8 ± 0.4 mmol/L, P < .05) than in the control trial. Total carbohydrate oxidation (302.3 ± 26.2 v 265.5 ± 11.7 μmol · min-1 · kg-1, P < .06), estimated muscle glycogenolysis (270.7 ± 23.1 v 225.1 ± 9.7 μmol · min-1 · kg-1, p < .05), and plasma lactate concentration (7.9 ± 1.6 v 5.9 ± 1.1 mmol/L, P < .001) were also higher during the theophylline trial. These data suggest that adenosine may play a role in stimulating glucose uptake and restraining glycogenolysis but not in limiting lipolysis during exercise.
UR - http://www.scopus.com/inward/record.url?scp=0029738494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029738494&partnerID=8YFLogxK
U2 - 10.1016/S0026-0495(96)90016-5
DO - 10.1016/S0026-0495(96)90016-5
M3 - Article
C2 - 8781304
AN - SCOPUS:0029738494
SN - 0026-0495
VL - 45
SP - 1153
EP - 1160
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 9
ER -